secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001711279-25-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech Q1 VYJUVEK revenue $88.2M; net income $35.7M; EU approval secured
--------------------------------------------------------------------------------

- VYJUVEK net product revenue $88.2M in Q1 2025 (vs $45.3M Q1 2024); gross margin 94%.
- Net income $35.7M ($1.24 basic EPS) vs $0.9M ($0.03) year ago; cash $765.3M.
- European Commission approved VYJUVEK for DEB; first Germany launch mid-2025; Japan decision expected 2H2025.
- Second ophthalmic program KB801 IND cleared for neurotrophic keratitis; Phase 1/2 EMERALD-1 starts May 2025.
- FY2025 non-GAAP R&D+SG&A guidance $150-175M; upcoming readouts for CF, AATD, ocular DEB, aesthetics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000045/0001711279-25-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000045/krys-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001711279-25-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer